연구성과로 돌아가기

2023 연구자 정보 (69 / 1135)

※ 컨트롤 + 클릭으로 열별 다중 정렬 가능합니다.
Excel 다운로드
Author Name 제1저자 여부 교신저자 여부 Address ResearcherID ORCID Paper Title WoS Edition 최상위 JCR(%) WoS Category Related Email
Yamashita, Toshinari
(Yamashita, T)


[JCR상위 1.7] Trastuzumab deruxtecan (T-DXd) vs treatment of physician's choice (TPC) in patients (pts) with HER2-low, hormone receptor-positive (HR plus ) unresectable and/or metastatic breast cancer (mBC): Exploratory biomarker analysis of DESTINY-Breast04 SCIE 1.7 ONCOLOGY
Yang, Sung Woong
(Yang, SW)
Kyungpook Natl Univ KNU, Sch Mat Sci & Engn, Daegu 41566, South Korea
Kyungpook Natl Univ, Sch Mat Sci & Engn, Daegu 41566, South Korea
Kyungpook Natl Univ, Sch Mat Sci & Engn, Daegu, South Korea


[JCR상위 1.7] High-performance self-powered color filter-free blue photodetector based on wide-bandgap halide perovskites
[JCR상위 3.9] Ternary diagrams of phase, stability, and optical properties of cesium lead mixed-halide perovskites
[JCR상위 3.8] Regulating Surface Heterogeneity Maximizes Photovoltage and Operational Stability in Tin-Lead Perovskite Solar Cells
[JCR상위 3.1] High-throughput compositional mapping of triple-cation tin-lead perovskites for high-efficiency solar cells
SCIE 1.7 MATERIALS SCIENCE, MULTIDISCIPLINARY;METALLURGY & METALLURGICAL ENGINEERING
CHEMISTRY, PHYSICAL;ELECTROCHEMISTRY;ENERGY & FUELS;MATERIALS SCIENCE, MULTIDISCIPLINARY;NANOSCIENCE & NANOTECHNOLOGY
MATERIALS SCIENCE, MULTIDISCIPLINARY
wook2@knu.ac.kr;
donghoekim@korea.ac.kr;wook2@knu.ac.kr;
Yang, Won Jun
(Yang, WJ)


[JCR상위 1.7] Incidence, landscape and survival outcome of de novo malignancy after double lung transplantation.
[JCR상위 1.7] Machine learning models based on radiomics features to predict treatment response, biomarker status, and bone metastasis in patients with non-small cell lung cancer (NSCLC) treated with immune checkpoint inhibitors (ICIs)
SCIE 1.7 ONCOLOGY
Yared, Jean
(Yared, J)


[JCR상위 1.7] Ibrutinib for First-Line Treatment of Chronic Graft-Versus-Host Disease: Results From the Randomized Phase III iNTEGRATE Study SCIE 1.7 ONCOLOGY dmiklos@stanford.edu;
Yeh, Ta-Sen
(Yeh, TS)


[JCR상위 1.7] ATTRACTION-5: A phase 3 study of nivolumab plus chemotherapy as postoperative adjuvant treatment for pathological stage III (pStage III) gastric or gastroesophageal junction (G/GEJ) cancer SCIE 1.7 ONCOLOGY
Yi, Kiyoun
(Yi, K)
Pusan Natl Univ Hosp, Busan, South Korea

[JCR상위 1.7] Real-world experience of atezolizumab plus bevacizumab combination treatment in high risk patients with advanced hepatocellular carcinoma SCIE 1.7 GASTROENTEROLOGY & HEPATOLOGY jheo@pusan.ac.kr;
Yi, Min
(Yi, M)
Arrowhead Pharmaceut Inc, Pasadena, CA USA

[JCR상위 1.7] A phase I/II study of ARO-HSD, an RNA interference therapeutic, for the treatment of non-alcoholic steatohepatitis SCIE 1.7 GASTROENTEROLOGY & HEPATOLOGY mfyuen@hku.hk;
Yoo, Changhoon
(Yoo, C)
Univ Ulsan, Coll Med, Asan Med Ctr, Dept Oncol, 88 Olymp Ro,43 Gil, Seoul 05505, South Korea
Univ Ulsan, Asan Med Ctr, Dept Oncol, Coll Med, Seoul, South Korea


[JCR상위 1.7] Serum vitamin D3 levels and overall survival (OS) in patients (pts) with advanced biliary tract cancer (BTC): Analysis of the NIFTY trial cohort.
[JCR상위 3.6] Treatment With Liposomal Irinotecan Plus Fluorouracil and Leucovorin for Patients With Previously Treated Metastatic Biliary Tract Cancer The Phase 2b NIFTY Randomized Clinical Trial
[JCR상위 28.4] Recommendations for the Use of Next-Generation Sequencing and the Molecular Tumor Board for Patients with Advanced Cancer: A Report from KSMO and KCSG Precision Medicine Networking Group (vol 54, pg 1, 2022)
SCIE 1.7 ONCOLOGY yooc@amc.seoul.kr;
Yoo, Tae-Kyung
(Yoo, TK)


[JCR상위 1.7] Prospective single-arm study of endocrine therapies with ovarian function suppression in premenopausal patients with node-positive early breast cancer with low genomic risk (INTERSTELLAR trial, KBCSG-25)
[JCR상위 1.7] Omission of breast surgery for predicted pCR patients with MRI and vacuum-assisted biopsy in breast cancer after neoadjuvant chemotherapy: A multicenter, single-arm, non-inferiority trial (OPTIMIST trial)
SCIE 1.7 ONCOLOGY
Yoon, Chang Ik
(Yoon, CI)
IAP-6721-2023
Kim, Chang Gon

[JCR상위 1.7] Prospective single-arm study of endocrine therapies with ovarian function suppression in premenopausal patients with node-positive early breast cancer with low genomic risk (INTERSTELLAR trial, KBCSG-25) SCIE 1.7 ONCOLOGY
Yoon, Eileen
(Yoon, E)
Hanyang Univ, Coll Med, Seoul, South Korea

[JCR상위 1.7] The role of M2BPGi in screening for advanced hepatic fibrosis in diabetic patients
[JCR상위 1.7] The role of M2BPGi for screening of advanced hepatic fibrosis in elderly patients
[JCR상위 1.7] Fibrosis-4 and M2BPGi combination screening algorithm for screening advanced hepatic fibrosis in diabetes is cost-effective
SCIE 1.7 GASTROENTEROLOGY & HEPATOLOGY noshin@hanyang.ac.kr;
Yoon, Sung Mi
(Yoon, SM)


[JCR상위 1.7] Machine learning models based on radiomics features to predict treatment response, biomarker status, and bone metastasis in patients with non-small cell lung cancer (NSCLC) treated with immune checkpoint inhibitors (ICIs) SCIE 1.7 ONCOLOGY
Youn, Hyun Jo
(Youn, HJ)


[JCR상위 1.7] Prospective single-arm study of endocrine therapies with ovarian function suppression in premenopausal patients with node-positive early breast cancer with low genomic risk (INTERSTELLAR trial, KBCSG-25)
[JCR상위 1.7] Omission of breast surgery for predicted pCR patients with MRI and vacuum-assisted biopsy in breast cancer after neoadjuvant chemotherapy: A multicenter, single-arm, non-inferiority trial (OPTIMIST trial)
SCIE 1.7 ONCOLOGY
Youssoufian, Hagop
(Youssoufian, H)


[JCR상위 1.7] Phase 2 study of bavituximab (bavi), a first-in-class antibody targeting phosphatidylserine (PS), plus pembrolizumab (P) in advanced gastric or gastroesophageal junction (GEJ) cancer SCIE 1.7 ONCOLOGY
Yu, Jisang
(Yu, J)
Northwestern Univ, Feinberg Sch Med, Chicago, IL 60208 USA
Northwestern Mem Hosp, Dept Internal Med, Chicago, IL 60611 USA

0000-0002-4370-947X
Yu, Jisang
[JCR상위 1.7] Post-double lung transplantation survival outcomes of bilateral lung cancer and incidence of post-transplant lung cancer
[JCR상위 1.7] Incidence, landscape and survival outcome of de novo malignancy after double lung transplantation.
[JCR상위 67.0] Survival Outcomes After Double-Lung Transplantation for Refractory Lung-Limited Cancers and Incidence of Post-Transplant Lung Cancer
[JCR상위 19.0] A Comprehensive Landscape of De Novo Malignancy After Double Lung Transplantation
[JCR상위 1.7] Machine learning models based on radiomics features to predict treatment response, biomarker status, and bone metastasis in patients with non-small cell lung cancer (NSCLC) treated with immune checkpoint inhibitors (ICIs)
SCIE 1.7 ONCOLOGY
SURGERY;TRANSPLANTATION
ankit.bharat@nm.org;ychae@nm.org;
ychae@nm.org;
페이지 이동: